Alzamend Neuro, Inc.
ALZN- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001677077
In the last 90 days, Alzamend Neuro, Inc. insiders filed 1 open-market purchase and 1 sale; 12 institutions reported holding it in 13F filings for Q2 2026, worth $3.26M in total; no superinvestor holds it.
Q1 2024 vs. Q4 2023
How the institutions holding Alzamend Neuro, Inc. changed between Q4 2023 and Q1 2024.
All holders in Q1 2024All holders in Q4 2023
| Measure | Q4 2023 | Of which not filed for Q1 2024 | Q1 2024 | Change |
|---|---|---|---|---|
| Holders | 16 | 1 | 13 | −2 |
| Shares | 374.4K | 66 | 387.1K | +12.8K (+3.4%) |
| Value | $334.7K | $59 | $386.8K | +$52.1K (+15.6%) |
1 institution that held it in Q4 2023 haven't filed for Q1 2024 yet. Not filing isn't selling, so the changes leave them out.
New holders (1)
Institutions that held Alzamend Neuro, Inc. at the end of Q1 2024 but not at the end of Q4 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Virtu Financial LLC | 26,482 | $26.0K | 0.00% |
Sold out (3)
Institutions that held Alzamend Neuro, Inc. at the end of Q4 2023 and filed for Q1 2024 without it.
| Institution | Shares, Q4 2023 | Value, Q4 2023 |
|---|---|---|
| HRT Financial LP | 16,806 | $15.0K |
| UBS Group AG | 1,909 | $1.70K |
| Bank of America Corp | 47 | $42 |
Not filed for Q1 2024 yet (1)
Institutions that held Alzamend Neuro, Inc. at the end of Q4 2023 and haven't filed a 13F for Q1 2024. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q4 2023 | Value, Q4 2023 |
|---|---|---|
| Baystate Wealth Management LLC | 66 | $59 |